Aroa Biosurgery Limited Receivables

The latest receivables for ARX.AX is $34M as of March 2026. That compares with $15M in the prior-year period — up 128.0% year over year. Investors often review this figure alongside Aroa Biosurgery Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, ARX.AX's receivables moved from $15M to $34M — a 128.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aroa Biosurgery Limited's operating scale or balance-sheet position.

A receivables figure of $34M for ARX.AX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ARX.AX's receivables ($34M), review year-over-year change from $15M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.